The collaboration between Taizhou Kaimi Biotech and Scenesafe Trauma Scene Remediation marks a pivotal development in the field of drug residue detection in Canada. The introduction of the Unow™ Drug Residue Test Device, a portable solution capable of identifying trace amounts of dangerous substances such as opioids, fentanyl, and methamphetamine with laboratory-grade accuracy, is set to transform safety protocols across various sectors.
This innovative device is tailored for use by law enforcement during investigations, healthcare facilities striving for sterile environments, remediation teams verifying decontamination efforts, and property owners ensuring the safety of residential and commercial spaces. Otis Zhao, President and Founder of Taizhou Kaimi Biotech, underscored the device's role in community protection, while Hang Ai, Founder of Scenesafe, pointed out its critical importance in mitigating drug contamination risks for first responders, families, and businesses alike.
The partnership leverages Taizhou Kaimi Biotech's expertise in biotech innovation and Scenesafe's deep understanding of Canadian safety standards, aiming to set a new benchmark in drug residue detection and remediation. The Unow™ Drug Residue Test Device is expected to be available to Canadian clients by the second quarter of 2025, with pre-orders opening in the near future. This initiative not only advances portable diagnostic technologies but also significantly contributes to public safety solutions in Canada.
For more information on the Unow™ Drug Residue Test Device, visit https://www.taizhoukaimibiotech.com and https://www.scenesafe.com.
